Earnings summaries and quarterly performance for Bolt Biotherapeutics.
Executive leadership at Bolt Biotherapeutics.
Board of directors at Bolt Biotherapeutics.
Research analysts covering Bolt Biotherapeutics.
Recent press releases and 8-K filings for BOLT.
Boltive Appoints Pamela Slea as New CEO
BOLT
CEO Change
Management Change
Board Change
- Pamela Slea has been appointed Chief Executive Officer of Boltive and will join the Board of Directors, effective immediately.
- Slea succeeds Matt Kennedy, who transitions to Executive Chairman of the Board, and has appointed Catherine Mietek as Chief Marketing Officer.
- Slea brings over 20 years of adtech experience from pioneering companies, positioning Boltive to lead in the converging digital ad security and data privacy market.
Jan 22, 2026, 2:14 PM
Bolt Biotherapeutics Reports Q3 2025 Financial Results and Business Update
BOLT
Earnings
Guidance Update
- Bolt Biotherapeutics reported a cash balance of $38.8 million as of September 30, 2025, with an anticipated cash runway extending into 2027.
- The company expects to present initial clinical data for its BDC-4182 Phase 1 dose escalation study in the third quarter of 2026.
- For the third quarter ended September 30, 2025, collaboration revenue increased to $2.2 million compared to $1.1 million for the same quarter in 2024, while loss from operations decreased to $7.7 million from $16.4 million in the prior year period.
Nov 12, 2025, 9:05 PM
Bolt Biotherapeutics Provides BDC-4182 Update and Extends Cash Runway
BOLT
Layoffs
Guidance Update
New Projects/Investments
- Bolt Biotherapeutics now expects to report initial clinical data for its BDC-4182 Phase 1 dose escalation study in the third quarter of 2026, following a modification to the clinical trial protocol.
- To conserve capital and extend its cash runway into 2027, the company is implementing a 50% workforce reduction, impacting approximately 20 employees.
- The company anticipates incurring pre-tax charges of approximately $1.5 million to $2.0 million related to the workforce reduction, primarily for severance and benefits, which are expected to be recorded in the fourth quarter of 2025.
Oct 2, 2025, 8:05 PM
Bolt Biotherapeutics Updates BDC-4182 Clinical Data Timeline and Announces Workforce Reduction
BOLT
Layoffs
Guidance Update
- Bolt Biotherapeutics now expects to report initial clinical data for its BDC-4182 Phase 1 dose escalation study in 3Q 2026, a delay attributed to modifying the clinical trial protocol.
- To conserve capital and extend its cash runway into 2027, the company is implementing a 50% workforce reduction.
Oct 1, 2025, 8:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more